☰

Dina Stepanova - Publications

Affiliations: 
Pirogov Russian National Research Medical University 
Tree Info Grants Similar researchers PubMed Report error

9 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Stepanova DS, Braun L, Chernoff J. A new concept in NF2 pharmacotherapy: targeting fatty acid synthesis. Oncoscience. 5: 126-127. PMID 30035161 DOI: 10.18632/oncoscience.417  0.487
2018 Semenova G, Stepanova D, Karchugina S, Dubyk C, Deyev S, Lazar A, Chernoff J. Abstract B066: Unique roles of group I PAK isoforms in regulating MPNST cell viability Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B066  0.546
2017 Stepanova DS, Semenova G, Kuo YM, Andrews AJ, Ammoun S, Hanemann CO, Chernoff J. An essential role for the tumor suppressor Merlin in regulating fatty acid synthesis. Cancer Research. PMID 28729415 DOI: 10.1158/0008-5472.Can-16-2834  0.7
2017 Semenova G, Stepanova DS, Dubyk C, Handorf E, Deyev SM, Lazar AJ, Chernoff J. Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis. Oncogene. PMID 28534510 DOI: 10.1038/Onc.2017.143  0.731
2017 Semenova G, Stepanova D, Deyev SM, Chernoff J. Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis type I. Biochimie. PMID 28065690 DOI: 10.1016/J.Biochi.2017.01.001  0.696
2015 Stepanova DS, Chernoff J, Shimanovskiy NL. Search for Chemical Compounds for Pharmacotherapy of Neurofibromatosis Type 2 Pharmaceutical Chemistry Journal. 48: 777-782. DOI: 10.1007/S11094-015-1194-Z  0.536
2012 Chow HY, Jubb AM, Koch JN, Jaffer ZM, Stepanova D, Campbell DA, Duron SG, O'Farrell M, Cai KQ, Klein-Szanto AJ, Gutkind JS, Hoeflich KP, Chernoff J. p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model. Cancer Research. 72: 5966-75. PMID 22983922 DOI: 10.1158/0008-5472.Can-12-2246  0.652
2011 Stepanova D, Chernoff J. PAK1 (p21/Cdc42/Rac1-activated kinase 1 (STE20 homolog, yeast)) Atlas of Genetics and Cytogenetics in Oncology and Haematology. DOI: 10.4267/2042/38554  0.515
2010 Chow HY, Stepanova D, Koch J, Chernoff J. p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. Plos One. 5: e13791. PMID 21072183 DOI: 10.1371/Journal.Pone.0013791  0.693
Show low-probability matches.